EP3383883 - SALTS OF CONJUGATES FOR CANCER THERAPY [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 09.04.2021 Database last updated on 22.08.2024 | |
Former | Request for examination was made Status updated on 07.09.2018 | ||
Former | The international publication has been made Status updated on 15.06.2017 | Most recent event Tooltip | 11.10.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states BioSight Ltd. 3 Hayarden Street Airport City, P.O.Box 1083 Lod 7019802 / IL | [2019/44] |
Former [2018/41] | For all designated states BioSight Ltd. 1 Hayarden St. Airport City P.O.B 1083 Lod 7019802 / IL | Inventor(s) | 01 /
GENGRINOVITCH, Stela HaEla 208 2010800 Kfar Hanania / IL | [2018/41] | Representative(s) | Pearl Cohen Zedek Latzer Baratz UK LLP The Gridiron Building One Pancras Square London N1C 4AG / GB | [N/P] |
Former [2018/41] | Becker Kurig Straus Patentanwälte Bavariastrasse 7 80336 München / DE | Application number, filing date | 16870129.0 | 01.12.2016 | [2018/41] | WO2016IL51287 | Priority number, date | US201562262428P | 03.12.2015 Original published format: US 201562262428 P | WO2016IL50077 | 25.01.2016 Original published format: PCT/IL2016/050077 | US201662370257P | 03.08.2016 Original published format: US 201662370257 P | [2018/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017094011 | Date: | 08.06.2017 | Language: | EN | [2017/23] | Type: | A1 Application with search report | No.: | EP3383883 | Date: | 10.10.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.06.2017 takes the place of the publication of the European patent application. | [2018/41] | Search report(s) | International search report - published on: | IL | 08.06.2017 | (Supplementary) European search report - dispatched on: | EP | 21.06.2019 | Classification | IPC: | A61K31/7068, A61P35/00, A61P35/02, A61P31/12, A61K47/54, C07H19/06, C07H19/09 | [2019/30] | CPC: |
C07H19/09 (EP,US);
C07H19/067 (IL);
A61K47/542 (EP,IL,RU,US);
A61P35/00 (RU);
A61P35/02 (EP,RU,US);
A61P35/04 (EP,US);
C07H19/06 (EP,IL,RU,US)
(-)
|
Former IPC [2018/41] | C07H19/06, C07H19/067, A61P35/00, A61P35/02, A61K31/7068, A61K47/50 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/41] | Title | German: | SALZE VON KONJUGATEN ZUR KREBSTHERAPIE | [2018/41] | English: | SALTS OF CONJUGATES FOR CANCER THERAPY | [2018/41] | French: | SELS DE CONJUGUÉS EN CANCÉRO-THÉRAPIE | [2018/41] | Entry into regional phase | 22.05.2018 | National basic fee paid | 22.05.2018 | Search fee paid | 22.05.2018 | Designation fee(s) paid | 22.05.2018 | Examination fee paid | Examination procedure | 22.05.2018 | Examination requested [2018/41] | 22.05.2018 | Date on which the examining division has become responsible | 20.01.2020 | Amendment by applicant (claims and/or description) | 09.04.2021 | Despatch of a communication from the examining division (Time limit: M04) | 17.08.2021 | Reply to a communication from the examining division | 11.11.2022 | Despatch of a communication from the examining division (Time limit: M04) | 20.03.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 12.12.2018 | Renewal fee patent year 03 | 13.12.2019 | Renewal fee patent year 04 | 14.12.2020 | Renewal fee patent year 05 | 30.11.2021 | Renewal fee patent year 06 | 13.10.2022 | Renewal fee patent year 07 | 11.10.2023 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]JPH0859688 (MITSUI TOATSU CHEMICALS) [I] 1-4,8-11 * compound 8 * * claim 1 *; | [I]US2011275590 (GENGRINOVITCH STELA [IL], et al) [I] 1-15 * paragraph [0125] * * example 17 * * claims 2,3,7-10,12-17 *; | [I] - Anonymous, "Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (BSTPHASE1-01)", ClinicalTrials.gov, Internet, (20150909), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/show/record/NCT02544438?view=record, (20190603), XP055593324 [I] 1-15 * the whole document * | International search | [Y]US7989188 (GENGRINOVITCH STELA [IL], et al) [Y] 1-46 * Whole document *; | [Y]WO2015178265 (NIPPON KAYAKU KK [JP]) [Y] 1-46 * Whole document *; | [Y]CN101812105 (UNIV SHENYANG PHARMACEUTICAL) [Y] 1-46 * Whole document *; | [A]US2014227282 (NISHITANI SHINOBU [JP], et al) [A] 1-38 * Whole document *; | [Y] - SINGH, V.K. et al., "Development of reversible glutamine conjugate of methotrexate for enhanced brain delivery.", Medicinal Chemistry Research, vol. 24, no. 2, (20150000), pages 624 - 635, (20140720), XP 035427193 [Y] 1-46 * Whole document * | [Y] - MING-JI JIN et al., "Synthesis and In-vitro Evaluation of N4-Amino Acid Derivatives of Cytarabine for Improving the Oral Delivery of Cytarabine.", Journal of Pharmaceutical Investigation, vol. 38, no. 4, (20080000), pages 255 - 259, (20080430), XP 055387237 [Y] 1-46 * Whole document * | [X] - HASABELNABY, S. et al., "Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.", European journal of medicinal chemistry, (20120000), vol. 55, pages 325 - 334, XP 055387239 [X] 1-46 * Whole document, especially Scheme 3, compounds 17 and 18; par. 4.1.6.b, 4.1.6.7 and 4.1.6.8 * | [A] - WECHTER, W. J. et al., "Nucleic acids. 16. Orally active derivatives of ara-cytidine.", Journal of medicinal chemistry, (19760901), vol. 19.8, pages 1013 - 1017, XP005538724 [A] 1-38 * Whole document * | [A] - LIU, B. et al., "Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine.", European journal of medicinal chemistry, (20090000), vol. 44, no. 9, pages 3596 - 3600, XP 026322187 [A] 1-46 * Whole document * | [A] - PRADEEPKUMAR L. PATEL., "Targeting GRP78 in Cancer with Nucleic Acid Bioconjugates.", Ph.D. Thesis., Seton Hall University South Orange, NJ, USA, (20140800), XP 055387248 [A] 1-46 * Scheme 2.2, compound 2.6; Paragraph 2.3.6; Fig. 2.10 * | [A] - CHHIKARA B.S. et al., "Development of cytarabine prodrugs and delivery systems for leukemia treatment.", Expert opinion on drug delivery, (20100000), vol. 7, no. 12, pages 1399 - 1414, XP 055387250 [A] 1-38 * Fig. 3 * |